Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H52O |
| Molecular Weight | 416.7226 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
InChI
InChIKey=LGJMUZUPVCAVPU-HRJGVYIJSA-N
InChI=1S/C29H52O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h19-27,30H,7-18H2,1-6H3/t20-,21-,22+,23+,24+,25-,26+,27+,28+,29-/m1/s1
| Molecular Formula | C29H52O |
| Molecular Weight | 416.7226 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Stigmastanol is a plant lipid molecule that resembles cholesterol in structure. It inhibits cholesterol absorption. Sitostanol powder (1 g) reduced cholesterol absorption by only 11.3 /- 7.4% (P = 0.2), confirming in vitro data showing poor solubility of sitostanol powder in artificial bile. In contrast, sitostanol in lecithin micelles reduced cholesterol absorption by 36.7 /- 4.2% (P = 0.003) at a dose of 700 mg and by 34.4 /- 5.8% (P = 0.01) at a dose of 300 mg. Stigmasterol, which is used for the synthesis of progesterone and vitamin D3 is a potential anti-inflammatory compound. Its action is mediated by the inhibition of several pro-inflammatory and matrix degradation mediators involved in osteoarthritis-induced cartilage degradation.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4984 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25356831 |
|||
Target ID: CHEMBL2808 |
136.0 nM [EC50] | ||
Target ID: CHEMBL4093 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16150823 |
110.0 nM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16035372
Curator's Comment: The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol (Stigmastanol) and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt. https://clinicaltrials.gov/ct2/show/NCT01406106
From a total number of 137 male subjects with hypercholesterolemia, eight subjects with the lowest and eight subjects with the highest ratios of lathosterol to campesterol in serum were included in the study. They received 1 g sitostanol (Stigmastanol)-supplemented margarine b.i.d. for four weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25356831
Mouse bone marrow derived macrophages incubated with plant stanols produced
less Tnf-a after exposure to sitostanol (Stigmastanol), both after 0.6 and 1.2 um
concentrations as compared to cyclodextrin (carrier control).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:17 GMT 2025
by
admin
on
Mon Mar 31 17:46:17 GMT 2025
|
| Record UNII |
C2NJ9WO6O7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C68422
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
||
|
LOINC |
74887-1
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
||
|
DSLD |
2050 (Number of products:4)
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
||
|
DSLD |
1905 (Number of products:6)
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
||
|
DSLD |
4138 (Number of products:1)
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
241572
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
83-45-4
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
m10213
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB129669
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
100000155633
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
49081
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
DTXSID201016169
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
201-479-0
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
Stigmastanol
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
C2NJ9WO6O7
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
C68323
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
C021255
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY | |||
|
89400
Created by
admin on Mon Mar 31 17:46:17 GMT 2025 , Edited by admin on Mon Mar 31 17:46:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |